MiMedx Group (MDXG) Reports Q4 Loss of $0.17/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
MiMedx Announces Fourth Quarter and Full Year 2020 Financial and Operating Results
March 8, 2021 5:32 PM ESTFourth Quarter Net Sales of $68.5 million, Full Year 2020 Net Sales of $248.2 million
Company to Host Conference Call on March 9, 2021 at 9:30 AM ET
MARIETTA, Ga., March 08, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (MiMedx or the Company), an industry leader in utilizing birth tissue as a platform for regenerative medicine, today announced the filing of its 2020 Annual Report on Form 10-K for the period ended December 31, 2020.
Timothy R. Wright, MiMedx Chief Executive Officer, commented, 2020 was a foundational year for MiMedx, with significant accomplishments of... More
